A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS)

Inclusion Criteria: * The decision to prescribe ESL was made by the physician before and independently of his/her decision to include the patient in the study * Patients treated with one drug licensed for monotherapy in partial onset seizures * Based on the physician's clinical judgment, the patient seizure activity was not controlled sufficiently with a current monotherapy and it was in the patient's best interest to be prescribed adjunctive ESL * Patient was prescribed ESL no longer than 2 weeks before the baseline * Treatment with ESL was to be commenced in line with the drug's license and Eslicarbazepine Acetate (ESL) Summary of Product Characteristics (SPC) * Aged 18 years or older * Signed written informed consent Exclusion Criteria: * Patients that had started ESL outside the approved SPC at enrolment * Simultaneous participation in an interventional clinical trial